Welcome to our dedicated page for In8Bio SEC filings (Ticker: INAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IN8bio, Inc. filings document regulatory disclosures for a clinical-stage biopharmaceutical company developing γδ T cell therapies and γδ T cell engagers. Form 8-K reports cover operating and financial results, clinical updates for INB-200 and INB-400 in newly diagnosed glioblastoma, preclinical γδ T cell engager data, financing and capital-structure matters, and governance events.
Proxy materials describe annual-meeting voting matters, director elections, auditor ratification, equity incentive plan proposals, board oversight, executive compensation, and stockholder governance. The filings also identify INAB common stock registered on Nasdaq and provide formal records of material events affecting the company's pipeline, financing, and corporate governance.
IN8bio, Inc. Schedule 13G/A discloses that William Tai-Wei Ho beneficially owns 151,223 shares of common stock, representing 3.7% of the class on a diluted basis. The position comprises 85,112 shares held of record, 4,866 shares held by his minor children, 3,648 shares held by other relatives over which he holds an irrevocable proxy, plus 47,914 options and 9,683 warrants that are immediately or imminently exercisable.
The filing also details voting and dispositive power: 142,709 shares with sole voting and dispositive power and smaller amounts reported as shared power. This amendment updates ownership disclosure but does not show a >5% stake or an intent to control the company.